title: Effect of carbamylated erythropoietin on major histocompatibility complex expression and neural differentiation of human neural stem cells.
abstract: The expression of major histocompatibility complex (MHC) on human neural stem cells (hNSCs) is tightly related to the fate of these cells in transplantation, therefore strategies to relieve rejection and promote graft survival are necessary to be applied. This study investigated the effect of carbamylated erythropoietin (CEPO) on MHC expression and differentiation of hNSCs with or without IFN-gamma incubation. Results showed that low levels of MHC molecules were expressed on hNSCs and increased by IFN-gamma. CEPO enhanced MHC-I antigens in both proliferative and differentiated hNSCs, but decreased MHC-II antigens in differentiated hNSCs and those cells exposed to IFN-gamma. Furthermore, CEPO promoted neural differentiation of hNSCs and outgrowth of neurites. Western blot analysis revealed activation of Stat3, Stat5 and Akt during these processes. These results suggest that CEPO may have immunoregulatory function in hNSCs besides its neuroprotection.
authors.affiliation: Department of Pediatrics, The Second Affiliated Hospital, Harbin Medical University, Harbin, China.
authors.forename: Zhong-Qiu
authors.initials: ZQ
authors.lastname: Fu
authors.forename: Qing-Liang
authors.initials: QL
authors.lastname: Shao
authors.forename: Jing-Ling
authors.initials: JL
authors.lastname: Shen
authors.forename: Yu-Jing
authors.initials: YJ
authors.lastname: Zhang
authors.forename: Xia-Xia
authors.initials: XX
authors.lastname: Zhao
authors.forename: Li
authors.initials: L
authors.lastname: Yao
mesh_terms: D000730:Androstadienes / Q000494:pharmacology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology*; D002478:Cells, Cultured; D016207:Cytokines / Q000494:pharmacology; D053595:Embryonic Stem Cells / Q000187:drug effects / Q000502:physiology*; D004815:Epidermal Growth Factor / Q000494:pharmacology; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000494:pharmacology; D005333:Fetus; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D005434:Flow Cytometry / Q000379:methods; D018507:Gene Expression Regulation, Developmental / Q000187:drug effects*; D006649:Histocompatibility Antigens / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism; D016501:Neurites / Q000187:drug effects; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D012717:Sesquiterpenes / Q000494:pharmacology; D000077191:Wortmannin
chemical_list: D000730:Androstadienes; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D006649:Histocompatibility Antigens; D007166:Immunosuppressive Agents; D009419:Nerve Tissue Proteins; D012717:Sesquiterpenes; C488171:carbamylated erythropoietin; D016222:Fibroblast Growth Factor 2; D004921:Erythropoietin; C002669:parthenolide; D004815:Epidermal Growth Factor; D000077191:Wortmannin